Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapies for retinal diseases. Company news centers on its ophthalmology pipeline, including KIO-301, a molecular photoswitch program for retinitis pigmentosa, choroideremia and Stargardt disease, and KIO-104, a non-steroidal DHODH inhibitor for retinal inflammation.
Recurring updates include clinical-study publications and development progress, intellectual-property coverage for KIO-100 family formulations, collaboration and regional partnership activity, research-and-development spending, capital resources, equity financing, warrant transactions and management changes. Financial releases generally pair operating results with status reports on the company’s retinal-disease programs.
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in two upcoming investor conferences. On August 13, 2024, at 3:00 pm Eastern Time, CEO Brian Strem will present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. Additionally, on August 15, 2024, Strem will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.
Both presentations will be available via live webcast, with registration links provided. Replays of the presentations will be accessible on-demand for 90 days on Kiora's investor relations homepage (ir.kiorapharma.com). These conferences offer investors an opportunity to gain insights into Kiora's latest developments and future prospects.
Kiora Pharmaceuticals (NASDAQ: KPRX) has received Orphan Medicinal Product Designation from the European Medicines Agency for KIO-301, a small molecule photoswitch, to treat inherited retinal dystrophies (IRDs) including retinitis pigmentosa. This designation provides at least ten years of market exclusivity in Europe, along with other regulatory benefits. Kiora is finalizing the design of the Phase 2 trial (ABACUS-2) for KIO-301, set to begin later this year.
KIO-301 is designed to restore light-sensing capabilities to retinal ganglion cells in patients with IRDs. In January 2024, Kiora partnered with Théa Open Innovation for worldwide co-development and commercialization of KIO-301, excluding Asia. The upcoming ABACUS-2 trial will be a multi-center, double-masked, randomized, controlled, multiple-dose study focusing on vision restoration in individuals with retinitis pigmentosa.
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced that Eric Daniels, M.D., its Chief Development Officer, will present at the Jones Trading Healthcare Seaside Summit on July 15, 2024, at 6:15 PM Eastern Time.
This presentation will be accessible to investors both live and on-demand via a specific registration link, and an on-demand replay will be available for 90 days on Kiora's Investor Relations homepage.
Following the presentation, Kiora invites verified retail and institutional investors to submit questions regarding their clinical development plans, the science behind their investigational therapies, and financials. The Q&A portal opens on July 16 at 9:00 AM EDT and closes on July 19 at 11:00 AM EDT.
Questions can be submitted and upvoted through the dedicated Q&A portal.
Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Lisa Walters-Hoffert as an independent member of its Board of Directors, effective July 1, 2024. Walters-Hoffert, a seasoned biotech executive, will serve as chair of the audit committee and join the compensation committee. Concurrently, Ken Gayron will step down from the board due to other commitments.
Lisa Walters-Hoffert brings extensive experience in strategic development, governance, finance, and capital markets to Kiora. Her appointment comes at a time when Kiora is advancing its pipeline of retinal disease treatments. Recently, Kiora has reported promising data on KIO-301 for retinal diseases, established a strategic co-development partnership, and secured financial resources to support its operations for at least the next two years, including investment in KIO-104 for inflammatory retinal diseases.
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced the appointment of Dr. Roger A. Goldberg, a renowned vitreoretinal surgeon, to its Scientific Advisory Board on June 25, 2024. Dr. Goldberg, who is affiliated with Bay Area Retina Associates, brings extensive clinical and research expertise to Kiora. He has been involved in numerous clinical trials and has published extensively in top medical journals.
Dr. Goldberg will contribute to the development of Kiora's retinal disease therapeutics, including their investigational drug KIO-104, which targets overactive immune cells associated with conditions like macular edema and uveitis. His appointment is expected to enhance Kiora’s ability to advance treatment options for retinal diseases with high unmet needs. Dr. Goldberg’s background includes a medical degree from Yale, residency at Bascom Palmer Eye Institute, and a fellowship at Tufts University. He is board certified and actively engaged in several prestigious ophthalmology organizations.
Kiora Pharmaceuticals (NASDAQ: KPRX) will participate in two upcoming investor conferences. On May 22, at 3:00 pm ET, Executive VP of Finance Melissa Tosca will present at the WeBull Corporate Connect Biotech Investment Webinar. The event will be live and available on-demand for 90 days. On May 30, at 2:45 pm ET, President and CEO Brian Strem will join a virtual fireside chat at the Lytham Partners Spring 2024 Investor Conference. This event will also be live-streamed and available on-demand for 90 days. Kiora's management will hold one-on-one virtual meetings during the Lytham Partners event. Interested parties can arrange meetings by contacting Lytham Partners or registering for the event.
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) reported strong Q1 2024 financial results and updates on its retinal disease treatment pipeline. With $31.3 million in cash, Kiora is well-positioned to advance KIO-301 and KIO-104 into mid-stage clinical trials. The partnership with Théa Open Innovation (TOI) allows for efficient capital allocation. KIO-301 targets inherited retinal disorders, while KIO-104 addresses retinal inflammatory diseases. Positive milestones include successful Phase 1 trials and a strategic partnership with TOI. Financially, Kiora ended Q1 2024 with $31.3 million in cash, $16 million in revenue, and a net income of $13.5 million.
Kiora Pharmaceuticals (NASDAQ: KPRX) will be presenting at The Citizens JMP Life Sciences Conference on May 14th, 2024. Investors can access the online presentation live on the company's website and replay it for 90 days.
Kiora Pharmaceuticals released additional clinical data for KIO-301, a small molecule photoswitch, showing a significant increase in brain activity in the visual cortex of patients with retinitis pigmentosa. The data from the ABACUS-1 trial indicated improvements in visual field, visual acuity, and functional vision, along with an increase in neural activity that aligns with these improvements. The results were presented at the ARVO annual meeting by Professor Robert James Casson, supporting the drug's potential to restore vision.
Summary not available.